Trial Profile
Optical coherence tomography study of endothelisation of everolimus-eluting stents with abluminal bioabsorbable polymer at 3, 6 and 12 months
Status:
Active, no longer recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 20 Oct 2015
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Pharmacodynamics
- 20 Oct 2015 New trial record
- 02 Sep 2015 Interim results presented at ESC Congress 2015: Annual Congress of the European Society of Cardiology.